Steward Partners Investment Advisory LLC Invests $1.37 Million in CVS Health Corp (CVS)

Steward Partners Investment Advisory LLC bought a new position in CVS Health Corp (NYSE:CVS) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,796 shares of the pharmacy operator’s stock, valued at approximately $1,365,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Fieldpoint Private Securities LLC boosted its position in shares of CVS Health by 333.3% during the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after buying an additional 1,000 shares during the last quarter. Wealthcare Advisory Partners LLC boosted its position in shares of CVS Health by 330.3% during the third quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock valued at $105,000 after buying an additional 991 shares during the last quarter. Arcadia Investment Management Corp MI boosted its position in shares of CVS Health by 119.6% during the third quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock valued at $108,000 after buying an additional 726 shares during the last quarter. MPS Loria Financial Planners LLC purchased a new stake in shares of CVS Health during the second quarter valued at $119,000. Finally, Captrust Financial Advisors purchased a new stake in shares of CVS Health during the second quarter valued at $155,000. 80.81% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Corp (NYSE:CVS) opened at $69.79 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.02 and a quick ratio of 0.52. CVS Health Corp has a 12 month low of $66.45 and a 12 month high of $84.00. The company has a market capitalization of $70,700.00, a PE ratio of 11.83, a PEG ratio of 1.18 and a beta of 0.92.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 EPS for the quarter, topping the consensus estimate of $1.88 by $0.04. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The firm had revenue of $48.39 billion for the quarter, compared to the consensus estimate of $47.54 billion. During the same quarter last year, the company earned $1.71 earnings per share. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. research analysts expect that CVS Health Corp will post 6.44 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, February 2nd. Stockholders of record on Wednesday, January 24th were paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 2.87%. The ex-dividend date was Tuesday, January 23rd. CVS Health’s dividend payout ratio (DPR) is currently 33.90%.

In other news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the transaction, the executive vice president now owns 15,556 shares of the company’s stock, valued at $1,166,700. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.61% of the stock is owned by company insiders.

Several research firms recently commented on CVS. Robert W. Baird dropped their price objective on CVS Health from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, February 9th. Leerink Swann set a $85.00 price objective on CVS Health and gave the company a “buy” rating in a research report on Friday, February 9th. Royal Bank of Canada set a $89.00 target price on CVS Health and gave the company a “buy” rating in a report on Thursday, February 8th. Citigroup set a $77.00 target price on CVS Health and gave the company a “neutral” rating in a report on Tuesday. Finally, ValuEngine downgraded CVS Health from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $87.82.

COPYRIGHT VIOLATION WARNING: This report was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.themarketsdaily.com/2018/02/15/steward-partners-investment-advisory-llc-invests-1-37-million-in-cvs-health-corp-cvs.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply